Please wait...
Community genetics in real time: Congenital anomalies and genetic disorders in an Israeli Arab town with elevated consanguinity
Alyn Hospital
Israel
Biography
Gary Diamond, is known for his pioneering research on the neurodevelopmental effects of congenital HIV infection in newborns during his disabilities training at the Rose F. Kennedy Center at the Albert Einstein College of Medicine in New York. He went on to investigate developmental impairments from early emotional and environmental deprivation among foster care children in New York City, as well as among youngsters adopted from orphanages in Eastern Europe. He directed the child developmental services for the largest care provider in the public health system in the central district of the country, while holding an academic position and teaching at Tel Aviv University and the Schneider Children’s Medical Center over the past 30 years. His clinical and epidemiological research on trends and causes of the ongoing “epidemic” of Attention Deficit Disorders (ADHD) and Autism (ASD) Syndromes in a unique collaborative project with the world-renowned geneticist, Prof. Lutfi Jaber, as well as on other challenges, including use of stimulant medications for ADHD and maternal use of atypical antipsychotic treatments during pregnancy. He has served as member of the American Academy of Pediatrics, the American Academy of Cerebral Palsy and Developmental Medicine, as well as the director of the Ezer Mitzion and Aleh foundations for handicapped children, as well as a member of the Association for Early Childhood for the Arab Child, as well as the director of the cerebral palsy clinic at the Alyn Hospital for Child Rehabilitation in Jerusalem, serving both Israeli and Palestinian children.
DISCOVER
Speakers
Characteristic linguistic styles in young Arabic speaking children diagnosed with ASD
Alyn Hospital
Israel
Speakers
Investigating the cellular mechanisms underpinning the role of leptin and ghrelin and their receptors on hippocampal neurons
University of St Andrews
United Kingdom
Speakers
NRS-2002 scale impact on nutritional status screening of patients with acute cerebrovascular accident
Sechenov University
Russian Federation
Speakers
miRNA expression changes in PD blood leukocytes
UCL
UK
Gary Diamond presents at the Healthcore Bridge International Medical Conference 2026 — October 16, 2026, Hall B — Infectious Diseases & Immunology, Level 2.
FAQs
Prof. Tanaka will deliver an invited lecture titled 'Alzheimer's Therapeutics 2026: Translating Lecanemab Data to Clinical Reality' in the Neuroscience & Neurology track on Day 2. The presentation features 36-month real-world data from Japan and previews the next wave of anti-amyloid and anti-tau therapies.
Prof. Tanaka served as Asia-Pacific Principal Investigator for the CLARITY-AD Phase III trial of lecanemab. His team enrolled 342 participants across 18 sites in Japan and Korea, and biomarker data from his laboratory directly informed the patient selection criteria incorporated into approved prescribing guidance in Japan and the EU.
Prof. Tanaka's research supports blood-based p-tau217 as the primary screening and monitoring biomarker for anti-amyloid therapy. He also advocates for tau PET imaging at key decision points — particularly before treatment initiation and at 12 months — based on data from the CLARITY-J real-world registry.
Yes. Prof. Tanaka is Principal Investigator for two Phase III trials: one examining anti-tau monotherapy in early Alzheimer's, and one evaluating a dual anti-amyloid/anti-tau combination regimen. Both are currently enrolling across Japan, South Korea, and Singapore.
© 2026 Healthcore Bridge. All rights reserved. Advancing global healthcare through collaboration & innovation.